We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stanbio Expands International Distribution

By Labmedica staff writers
Posted on 14 Mar 2002
In a move to expand the distribution of its products, Stanbio Laboratory (Boerne, TX, USA) has agreed for BDS International Diagnostics Gmbh (Schwetzingen, Germany) to serve as the export sales office of Stanbio in Eastern and Western Europe, the Middle East, and the Indian subcontinent. More...
BDS' services will include supporting and managing existing distributors and selecting and training additional distributors.

Stanbio has been producing and marketing clinical diagnostic reagents and test kits since 1960. The company's in vitro diagnostic products include clinical chemistry, serology, pregnancy, urinalysis, occult blood, microbiology, hematology, blood-grouping products, and clinical instruments. Stanbio now supplies liquid-stable and dry-powder clinical reagents as well as innovative dry-chemistry systems.

"Our product offerings will be highly attractive to the European markets, and in BDS we have a partner who shares our philosophy of quality and service,” said William R. Pippin, president of Stanbio.




Related Links:
Stanbio
BDS

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
BKE-B
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.